Randomised trial of ifosfamide, carboplatin and etoposide with mid-cycle vincristine (VICE) versus standard practice chemotherapy in patients with limited small cell lung cancer (SCLC) and good performance status
Not Applicable
Completed
- Conditions
- CancerSmall cell lung cancer (SCLC)
- Registration Number
- ISRCTN47862456
- Lead Sponsor
- Medical Research Council (MRC) (UK)
- Brief Summary
2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16293867 results
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 402
Inclusion Criteria
1. Previously untreated SCLC
2. Limited disease
3. WHO 0-2
4. Normal blood count
5. Glomerular Filtration Rate (GFR) greater than 65 ml/min
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival time, quality of life
- Secondary Outcome Measures
Name Time Method ot provided at time of registration